Market Cap (In USD)
2.37 Billion
Revenue (In USD)
237 Thousand
Net Income (In USD)
-184.12 Million
Avg. Volume
12.48 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.731-3.98
- PE
- -
- EPS
- -
- Beta Value
- 0.515
- ISIN
- US3741631036
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Dr. John A. Scarlett M.D.
- Employee Count
- -
- Website
- https://www.geron.com
- Ipo Date
- 2018-01-29
- Details
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
More Stocks
-
7050
-
MCRMercor S.A.
MCR
-
3150
-
300580
-
002470
-
9250GRCS Inc.
9250
-
IGIFFIGM Financial Inc.
IGIFF
-
DEER